Clinical trial
Cisplatin, Metronomic Low-Dose Interferon Alfa, Gemcitabine, and Fever-Range…
NCT00082862 · The University of Texas Health Science Center, Houston, Other · Unknown status
Key facts
| NCT number | NCT00082862 |
|---|---|
| Title | Cisplatin, Metronomic Low-Dose Interferon Alfa, Gemcitabine, and Fever-Range Whole-Body Hyperthermia in Treating Patients With Inoperable or Metastatic Pancreatic Cancer |
| Official title | A Phase II Clinical Trial of a Timing/Schedule Optimized Combined-Modality Regimen: Cisplatin + Metronomic Low-Dose Interferon-α (IFN-α) Followed by Gemcitabine HCl (GEMZAR) in Combination With Mild, Fever-Range Whole-Body Hyperthermia (FR-WBH) in Patients With Advanced, Inoperable Pancreatic Cancer |
| Lead sponsor | The University of Texas Health Science Center, Houston, Other |
| Status | Unknown status |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Pancreatic Cancer |
| Intervention type | Biological, Drug, Procedure |
| Interventions | recombinant interferon alfa, cisplatin, gemcitabine hydrochloride, hyperthermia treatment |
| Enrollment | 48 |
| Start date | Jul 1, 2002 |
| Primary completion | Nov 1, 2012 |
| First posted | May 19, 2004 |
| Last update posted | Feb 13, 2012 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: